Skip to main content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Complementary and Alternative Medicine 1/2017

The Hippo signaling pathway: a potential therapeutic target is reversed by a Chinese patent drug in rats with diabetic retinopathy

BMC Complementary and Alternative Medicine > Ausgabe 1/2017
Gai-mei Hao, Tian-tian Lv, Yan Wu, Hong-liang Wang, Wei Xing, Yong Wang, Chun Li, Zi-jian Zhang, Zheng-lin Wang, Wei Wang, Jing Han
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12906-017-1678-3) contains supplementary material, which is available to authorized users.



The Hippo signaling pathway is reported to be involved in angiogenesis, but the roles of the Hippo pathway in diabetic retinopathy have not been addressed. Fufang Xueshuantong Capsule has been used to treat diabetic retinopathy in China; however, the effect of Fufang Xueshuantong Capsule on the Hippo pathway has not been investigated.


In this study, diabetes was induced in Sprague-Dawley rats with intraperitoneal injection of streptozotocin. Twenty weeks later, Fufang Xueshuantong Capsule was administered for 12 weeks. When the administration ended, the eyes were isolated for western blot and immunohistochemistry analyses. The levels of P- mammalian sterile 20-like (MST), large tumor suppressor homolog (Lats), P- yes-associated protein (YAP), transcriptional co-activator with PDZ binding motif (TAZ) and TEA domain family members (TEAD) were measured.


Diabetic rats had a decreased P-MST level in the inner plexiform layer and reduced expression of P-YAP in the photoreceptor layers of their eyes. In addition, diabetic rats displayed remarkable increases in Lats, TAZ and TEAD in their retinas. Furthermore, Fufang Xueshuantong Capsule restored the changes in the Hippo pathway.


The Hippo signaling pathway is important for the progression of diabetic retinopathy and will hopefully be a targeted therapeutic approach for the prevention of diabetic retinopathy.
Additional file 1: Data of the expreiment. (XLS 39 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Complementary and Alternative Medicine 1/2017 Zur Ausgabe